title: Transcatheter aortic valve implantation: a single-center experience of 300 cases.
abstract: BACKGROUND
  Transcatheter aortic valve implantation (TAVI) has recently become an alternative to surgical aortic valve replacement in selected patients with high operative risk.
  
  
  OBJECTIVE
  To investigate the 30 day clinical outcome of the first 300 consecutive patients treated with transfemoral TAVI at the Tel Aviv Medical Center.
  
  
  METHODS
  The CoreValve was used in 250 patients and the Edwards-Sapien valve in 50. The mean age of the patients was 83 +/- 5.3 years (range 63-98 years) and the mean valve area 0.69 +/- 0.18 cm2 (range 0.3-0.9 cm2); 62% were women.
  
  
  RESULTS
  The procedural success rate was 100%, and 30 day follow-up was done in all the patients. The average Euro-score for the cohort was 26 +/- 13 (range 1.5-67). Total in-hospital mortality and 30 day mortality were both 2.3% (7 patients). Sixty-seven patients (22%) underwent permanent pacemaker implantation after the TAVI procedure, mostly due to new onset of left bundle brunch block and prolonged PR interval or to high degree atrioventricular block. The rate of stroke was 1.7% (5 patients). Forty-one patients (13.7%) had vascular complications, of whom 9 (3%) were defined as major vascular complications (according to the VARC definition).
  
  
  CONCLUSIONS
  The 30 day clinical outcome in the first 300 consecutive TAVI patients in our center was favorable, with a mortality rate of 2.3% and low rates of stroke (1.7%) and major vascular complications (3%).
authors.affiliation: Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. afinkel@tasmc.health.gov.il
authors.forename: Ariel
authors.initials: A
authors.lastname: Finkelstein
authors.forename: Edo Y
authors.initials: EY
authors.lastname: Birati
authors.forename: Yigal
authors.initials: Y
authors.lastname: Abramowitz
authors.forename: Arie
authors.initials: A
authors.lastname: Steinvil
authors.forename: Nechama
authors.initials: N
authors.lastname: Sheinberg
authors.forename: Simon
authors.initials: S
authors.lastname: Biner
authors.forename: Shmuel
authors.initials: S
authors.lastname: Bazan
authors.forename: Yanai
authors.initials: Y
authors.lastname: Ben Gal
authors.forename: Amir
authors.initials: A
authors.lastname: Halkin
authors.forename: Yaron
authors.initials: Y
authors.lastname: Arbel
authors.forename: Eyal
authors.initials: E
authors.lastname: Ben-Assa
authors.forename: Eran
authors.initials: E
authors.lastname: Leshem-Rubinow
authors.forename: Gad
authors.initials: G
authors.lastname: Keren
authors.forename: Shmuel
authors.initials: S
authors.lastname: Banai
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001024:Aortic Valve Stenosis / Q000150:complications / Q000401:mortality / Q000601:surgery*; D006328:Cardiac Catheterization; D015331:Cohort Studies; D005260:Female; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects*; D017052:Hospital Mortality; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome